학술논문

Predicting the course of Alzheimer’s progression
Document Type
article
Source
Brain Informatics. 6(1)
Subject
Information and Computing Sciences
Biomedical and Clinical Sciences
Dementia
Clinical Research
Aging
Bioengineering
Alzheimer's Disease
Brain Disorders
Acquired Cognitive Impairment
Neurodegenerative
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Neurosciences
Biomedical Imaging
4.2 Evaluation of markers and technologies
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
Neurological
Alzheimer’s Disease Neuroimaging Initiative
Alzheimer’s disease
Biomakers
Classification Clinical diagnosis
Disease trajectories
Joint mixed-effects models
Latent time shift
Model averaging
Multi-cohort longitudinal data
Multi-level Bayesian models
Predictions
Random forest
Biomedical and clinical sciences
Information and computing sciences
Language
Abstract
Alzheimer's disease is the most common neurodegenerative disease and is characterized by the accumulation of amyloid-beta peptides leading to the formation of plaques and tau protein tangles in brain. These neuropathological features precede cognitive impairment and Alzheimer's dementia by many years. To better understand and predict the course of disease from early-stage asymptomatic to late-stage dementia, it is critical to study the patterns of progression of multiple markers. In particular, we aim to predict the likely future course of progression for individuals given only a single observation of their markers. Improved individual-level prediction may lead to improved clinical care and clinical trials. We propose a two-stage approach to modeling and predicting measures of cognition, function, brain imaging, fluid biomarkers, and diagnosis of individuals using multiple domains simultaneously. In the first stage, joint (or multivariate) mixed-effects models are used to simultaneously model multiple markers over time. In the second stage, random forests are used to predict categorical diagnoses (cognitively normal, mild cognitive impairment, or dementia) from predictions of continuous markers based on the first-stage model. The combination of the two models allows one to leverage their key strengths in order to obtain improved accuracy. We characterize the predictive accuracy of this two-stage approach using data from the Alzheimer's Disease Neuroimaging Initiative. The two-stage approach using a single joint mixed-effects model for all continuous outcomes yields better diagnostic classification accuracy compared to using separate univariate mixed-effects models for each of the continuous outcomes. Overall prediction accuracy above 80% was achieved over a period of 2.5 years. The results further indicate that overall accuracy is improved when markers from multiple assessment domains, such as cognition, function, and brain imaging, are used in the prediction algorithm as compared to the use of markers from a single domain only.